Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?

To provide a summary and discussion of international guidelines, position statements, and consensus statements about focal therapy (FT) for prostate cancer (PCa). The results showed a lack of long‐term randomised data for FT. International Urological guidelines emphasised the need for more high‐quality clinical trials with robust oncological and toxicity outcomes. Consensus and position statements were heterogeneous. Well‐designed studies with long‐term follow‐up and robust clinical and toxicity endpoints are needed to improve our understanding of FT and create uniform guidelines to streamline management and follow‐up.